Using peripheral blood progenitor cells (PBPC) for transplantation in pediatric patients: A state-of-the-art review

Bone Marrow Transplantation

Volumn 26, Issue 12, 2000, Pages 1291-1298

  Diaz M A ^a   Kanold, J ^b   Vicent, M G ^a   Halle, P ^b   Madero, L ^a   Demeocq F ^a  

^a HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^b UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

CD34+ selection; Children; Large volume leukapheresis; PBPC transplantation

Indexed keywords

CD34 ANTIGEN; CYTOKINE;

ALLOGRAFT; ANTICOAGULATION; BLOOD CELL; CELL COUNT; CELL MOTILITY; CHILD; DATA ANALYSIS; DONOR; ETHICS; EXTRACORPOREAL CIRCULATION; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; INFUSION; MEDICAL INFORMATION; PEDIATRICS; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; REVIEW; SAFETY; VASCULAR ACCESS;

CHILD; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0034485973     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702725     Document Type: Review

References (101)

1. Clinical collection and use of peripheral blood stem cells in pediatric patients
2. Peripheral blood stem cell autotransplantation in treatment of childhood cancer
3. Isolation and storage of peripheral blood hematopoietic stem cells for auto-transplantation into children with cancer
4. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts
5. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor
6. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor)
7. Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donors
8. Allogeneic peripheral blood stem cell transplant in children
9. Allogeneic peripheral blood progenitor cell (PBPC) transplantation in children
10. Allogeneic peripheral blood progenitor cell (PBPC) transplantation in children with haematological malignancies
11. Collection and transplantation of peripheral blood stem cells in very small children weighting 20 kg or less
12. Successful blood stem cell collection and transplant in children weighing less than 25 kg
13. Peripheral blood progenitor cell collection by large-volume leukapheresis in low-weight children
14. Kinetics of hematopoietic progenitor cell release induced by G-CSF-alone in children with solid tumors and leukemias
15. Safe and efficient PBSC collection in the smallest of children (15 kg)
16. Pediatric large volume peripheral blood progenitor cell collections from patients under 25 kg: A primer
17. Collection and use of peripheral blood stem cells in young children with refractory solid tumors
18. Feasibility of a body weight below 20 kg
19. Peripheral blood stem cell (PBSC) collections after taxol, cyclophosphamide and recombinant human granulocyte colony-stimulating factor (rhG-CSF)
20. Increase in peripheral blood megakaryocyte progenitors following cancer therapy with high-dose cyclophosphamide and hematopoietic growth factors
21. Use of G-CSF alone to mobilize peripheral blood stem cells for collection from children
22. Collection and transplantation of peripheral blood progenitor cells mobilized by G-CSF alone in children with malignancies
23. + cells
24. Mobilization and harvesting of peripheral blood stem cells: A randomized dose escalation trial of filgrastim
25. G-CSF 20 μg/kg/day vs 10 μg/kg/day for peripheral blood stem cell mobilization in children can minimize the duration of priming
26. Recommendations on the use of colony-stimulating factors in children: Conclusions of a European panel
27. Allogeneic blood stem cell transplantation: Considerations for donors
28. The biology and clinical uses of blood stem cells
29. Peripheral blood stem cell mobilization with granulocyte colony-stimulating factor and a harvesting procedure in pediatric donors
30. Efficacy of the mobilization of peripheral blood stem cells by granulocyte colony-stimulating factor in pediatric donors
31. Peripheral blood progenitor cell (PBPC) collection by large-volume leukapheresis from pediatric donors
32. Use of minors as bone marrow donors: Current attitude and management. A survey of 56 pediatric transplantation centers
33. Clinical toxicity and laboratory effects of granulocyte colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures
34. Biologic and clinical effects of granulocyte colony-stimulating factor in normal individual
35. Transient neutropenia in normal donors after G-CSF mobilization and stem cell apheresis
36. Administration of recombinant human granulocyte colony-stimulating factor to normal donors: Results of the Spanish national donor registry
37. Peripheral blood stem cell mobilization and apheresis: Analysis of adverse events in 94 normal donors
38. Three to 6-year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor
39. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): Occurrence in an allogeneic donor of peripheral blood stem cells
40. Acute iritis induced by granulocyte colony-stimulating factor used for mobilization in a volunteer unrelated peripheral blood progenitor cell donor
41. Apparent reactivation of a red cell alloantibody in a healthy individual after G-CSF administration
42. + cells: A pediatric experience
43. + progenitor cells: Feasibility and purging efficacy in pediatric patients with neuroblastoma
44. Analysis of engraftment kinetics in pediatric patients undergoing autologous PBPC transplantation
45. Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients
46. Single institution experience with mobilization, harvesting, and reinfusion of peripheral blood stem cells in children with a solid tumor or leukemia
47. + cell dose in engraftment kinetics
48. Peripheral blood stem cell autografts for treatment of childhood cancer: A review of the Japanese experience
49. Large-volume leukapheresis procedure for peripheral progenitor cell collection in children weighting 15 kg or less: Efficacy and safety evaluation
50. Non-tunneled catheters for the collection and transplantation of peripheral blood stem cells in children
51. Tunneled, double lumen Broviac catheters are useful, efficient and safe in children undergoing peripheral blood progenitor cell harvesting and transplantation
52. Peripheral stem cell (PBSC) collection in extremely low-weight infants
53. Specificities and optimization of peripheral blood stem cell collection in children: Treatment for malignancies can be mobilization
54. Autotransplants with peripheral blood stem cells and clinical results obtained in children: A review
55. Evaluation of Fresenius cell separator AS 104 for harvesting peripheral blood stem cells in pediatric patients
56. Peripheral blood progenitor cell collections in children with low platelet counts are safe
57. Experience with peripheral blood stem cell collection for autografts in children with active cancer
58. Collection of peripheral blood stem cells in pediatric patients: A concise review on technical aspects
59. + cell count predicts progenitor cell yield
60. Large-volume leukapheresis for peripheral blood stem cell collection in children: A simplified single-apheresis approach
61. + marrow cells in patient with breast cancer or neuroblastoma
62. Antigenic analysis of hematopoiesis. III: A hematopoietic progenitor cell surface antigen defined by monoclonal antibodies against KG1 cells
63. + cells purified from leukapheresis products
64. High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation
65. Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma
66. A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy
67. + cell transplantation procedure using standard leukapheresis products in very small children
68. + cell immunoselection from G-CSF-alone primed peripheral blood in children with low body mass
69. + cells for autografting in children
70. + cells for patients with multiple myeloma
71. Gene-marking to trace origin of relapse after autologous bone marrow transplantation
72. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells
73. Molecular monitoring of tumor cell contamination in leukapheresis products from stage IV neuroblastoma patients before and after positive CD34 selection
74. Immunological and molecular detection of tumor contamination in leukapheresis products from children with disseminated neuroblastoma: Implication for evaluation of tumor cell depletion after CD34 selection
75. Allogeneic peripheral blood stem cell transplantation in children with hematological malignancies from HLA-matched siblings
76. Allogeneic peripheral blood stem cell transplantation in children with hematologic malignancies
77. + transplantation in children with neuroblastoma
78. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: Hematologic recovery and costs. A randomized, controlled trial
79. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: A multivariate analysis in 218 patients treated in a single institution
80. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative therapy
81. Factors that influence collection and engraftment of autologous peripheral blood stem cells
82. Peripheral blood stem cells (PBSCs) collected after recombinant human granulocyte colony-stimulating factor (rhG-CSF): An analysis of factors correlating with the tempo of engraftment after transplantation
83. + cells and rapid hematopoietic recovery after peripheral blood stem-cell transplantation
84. Progenitor cell subsets and engraftment kinetics in children undergoing autologous peripheral blood stem cell transplantation
85. + blood cells predicts the colony-forming capacity of leukapheresis products in children
86. + cell dose
87. Allogeneic transplantation of blood-derived, T-cell depleted hematopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia
88. Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation
89. Peripheral blood stem cell pheresis in normal donors: Feasibility and yield of second collections
90. Blood stem cell procurement: Donor safety issues
91. Allogeneic transplantation with blood-stem cells mobilized by rhG-CSF for hematological malignancies
92. Allogeneic peripheral blood progenitor cell transplantation: Analysis of short-term engraftment and acute GVHD incidence in 33 cases
93. Allogeneic blood cell transplantation for hematological malignancy: Preliminary comparison of outcomes with bone marrow transplantation
94. Allogeneic peripheral blood stem cell transplantation for haematological malignancies - An analysis of kinetics of engraftment and GVHD risk
95. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies
96. Allogeneic transplantation in children
97. Allogeneic transplantation of peripheral blood progenitor cells in children: Experience of two pediatric centers
98. Cytokine-mobilized allogeneic peripheral blood stem cell transplants in children result in rapid and a high incidence of chronic GVHD
99. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease
100. High incidence of chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation
101. Graft-versus-leukemia reactions after bone marrow transplantation